Immuneering gains on FDA nod for early-stage study on cancer drug

Immuneering

30/09/2022 20:29

** Shares of Immuneering Corp  IMRX.O  jump 23% to $16.17 -
on track for their fifth straight session of gains 
    ** Stock among top pct gainers on the Nasdaq Biotechnology
Index  .NBI  
    ** Biotech says the U.S. Food and Drug Administration has
allowed co to test its drug candidate, IMM-1-104, in patients
with advanced tumors caused by mutation of a protein known as
RAS   urn:newsml:reuters.com:*:nGNX9n2C4c
    ** Co expects to enroll first patient in early-stage study
for IMM-1-104 in Q4 2022 
    ** Jefferis raises IMRX's price target to $16 from $14,
citing that it remains optimistic about IMRX's drug's
best-in-class potential 
    ** Brokerage expects data from early-stage trial in late
2023 
    ** Including session, stock down ~8% vs ~20% fall in .NBI
YTD 
 (Reporting by Bhanvi Satija in Bengaluru)
 ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91
9873062788;))